ESMO 2026: Adjuvant Cemiplimab in High-Risk CSCC
Updated results from the C-POST trial highlight the role of adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma (CSCC). In this MEDtalk from ESMO 2026, Dr. Vishal Patel, MD, FAAD, FACMS, Associate Professor of Dermatology and Director of the Cutaneous Oncology Program, George Washington University Cancer Center, USA, discusses the reduction in recurrence risk following surgery and radiation therapy. The updated data also show a trend towards improved overall survival, highlighting the importance of early treatment in patients at particularly high risk of recurrence.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in







